After the Illinois state court recently found GSK not liable for a case of cancer supposedly linked to its Zantac drug, the FTSE 100 pharmaceutical company announced another favourable ruling on Friday in the ongoing litigation against them.
A Florida State Court has ruled to exclude a plaintiffs’ testimony in a case against GSK regarding the alleged link between ranitidine and prostate cancer. The court deemed the expert testimony unreliable, failing to meet the Daubert standard for scientific evidence.
This ruling mirrors a similar decision made in December 2022 by Judge Rosenberg in the federal multidistrict litigation (MDL). In that case, all expert evidence presented by the plaintiffs was rejected, leading to the dismissal of MDL cases alleging various types of cancer, including bladder, esophageal, gastric, liver, and pancreatic.
GSK has announced its intention to seek dismissal of this case following the court’s ruling.
GSK emphasised that this ruling ensures that “unreliable and litigation-driven science” will not be permitted in the courtroom. The company maintains its stance and continues to “defend itself vigorously” against all remaining claims in other jurisdictions.
This latest development marks another victory for GSK in the ongoing litigation surrounding ranitidine, reinforcing the company’s position that the scientific evidence does not support claims of a causal link between the drug and cancer.